CORDIS
EU research results

CORDIS

English EN

TARGETING HIV INTEGRATION CO-FACTORS, TARGETING CELLULAR PROTEINS DURING NUCLEAR IMPORT OR INTEGRATION OF HIV

Project information

Grant agreement ID: 201032

Status

Closed project

  • Start date

    1 March 2008

  • End date

    29 February 2012

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 899 101,77

  • EU contribution

    € 2 939 672

Coordinated by:

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

Objective

Standard therapy of infection with the human immunodeficiency virus type 1 (HIV-1) is based on potent cocktails of drugs targeting viral proteins. This treatment is associated with severe side effects and is almost unaffordable for the patients living in sub-Saharan Africa. Incomplete suppression of HIV replication results in drug-resistance. Therefore, a continued research effort is required to develop more potent, cheaper and less toxic antivirals. The insight has grown that HIV requires cellular proteins to serve as co-factors for viral replication. Our over-all objective is to develop novel drugs by targeting co-factors required for HIV replication. The virus will find it difficult to develop antiviral resistance against drugs targeting interaction between invariable cellular proteins and conserved viral protein domains. We will focus on the cellular proteins that mediate HIV trafficking, nuclear import and integration, such as Lens Epithelium Derived Growth Factor (LEDGF/p75), a novel cofactor of HIV-1 integration. THINC is composed of 3 virologists, 2 medicinal chemists, 1 virologist from South Africa, 1 structural biologist, 1 pharmaceutical company. Our first objective is to identify and validate novel co-factors of HIV trafficking, nuclear import and integration as novel targets for anti-HIV therapy. The second objective is to develop new drugs against the validated cellular target LEDGF/p75. The third objective is to perform this work in the perspective of those who will benefit most: the HIV infected people all over the world. The initial steps of target validation and hit identification will mainly be taken by academic groups, while optimization and (pre)clinical development of drugs requires the participation of Tibotec, a European company devoted to the development of antiviral drugs. The project will also increase our generic understanding of protein-protein interactions (PPI).

Coordinator

KATHOLIEKE UNIVERSITEIT LEUVEN

Address

Oude Markt 13
3000 Leuven

Belgium

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 894 733,72

Administrative Contact

Marleen Verlinden (Ms.)

Participants (10)

SCUOLA NORMALE SUPERIORE

Italy

EU Contribution

€ 228 549,95

UNIVERSITA DEGLI STUDI DI SIENA

Italy

EU Contribution

€ 352 002

UNIVERSITA DEGLI STUDI DI MESSINA

Italy

EU Contribution

€ 285 200

TIBOTECH PHARMACEUTICALS LTD

Ireland

UNIVERSITY OF KWAZULU-NATAL

South Africa

EU Contribution

€ 226 505

USTAV ORGANICKE CHEMIE A BIOCHEMIE, AV CR, V.V.I.

Czechia

EU Contribution

€ 227 600

UNIVERSITE DE GENEVE

Switzerland

EU Contribution

€ 404 600

UNIVERSITA DEGLI STUDI DI PERUGIA

Italy

EU Contribution

€ 66 000

JANSSEN INFECTIOUS DISEASES DIAGNOSTICS BVBA

Belgium

EU Contribution

€ 72 881,44

UNIVERSITA DEGLI STUDI DI TRENTO

Italy

EU Contribution

€ 181 599,89

Project information

Grant agreement ID: 201032

Status

Closed project

  • Start date

    1 March 2008

  • End date

    29 February 2012

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 899 101,77

  • EU contribution

    € 2 939 672

Coordinated by:

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium